Helicobacter pylori OMP Antibody (BDI176): sc-57779

Helicobacter pylori OMP Antibody (BDI176) is a mouse monoclonal IgG1 antibody that detects the outer membrane protein (OMP) of Helicobacter pylori in non-species reactive applications such as western blotting (WB) and immunofluorescence (IF). Anti-Helicobacter pylori OMP antibody (BDI176) is available as a non-conjugated format. Helicobacter pylori is a Gram-negative bacterium that colonizes the mucus lining of the stomach and duodenum, leading to conditions such as peptic ulcers, gastritis, and duodenitis. Approximately 66% of the global population is infected with this bacterium, although many remain asymptomatic. The unique spiral shape of Helicobacter pylori allows survival in the highly acidic environment of the stomach, where Helicobacter pylori can be found in various locations, including the mucus layer, attached to epithelial cells, or within vacuoles of epithelial cells. OMPs play a crucial role in the bacterium′s ability to adhere to host tissues, facilitating the binding to membrane-associated lipids and carbohydrates through the production of adhesins. This adhesion is vital for colonization and persistence in the gastric niche, triggering signal transduction events in host cells that can influence local immune responses. Additionally, Helicobacter pylori utilizes a hydrogenase enzyme to derive energy from molecular hydrogen produced by other intestinal bacteria, and secretes urease to convert urea into ammonia and bicarbonate, effectively neutralizing stomach acidity. The multifaceted roles of OMPs underscore their importance in the pathogenesis of infections caused by Helicobacter pylori, making Helicobacter pylori OMP antibody (BDI176) an essential tool for researchers studying bacterial biology and associated diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Helicobacter pylori OMP Antibody (BDI176) References:

1. ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection.  |  Logan, RP. and Walker, MM. 2001. BMJ. 323: 920-2. PMID: 11668141
2. Molecular hydrogen as an energy source for Helicobacter pylori.  |  Olson, JW. and Maier, RJ. 2002. Science. 298: 1788-90. PMID: 12459589
3. Review article: inflammation-related promotion of gastrointestinal carcinogenesis--a perigenetic pathway.  |  Tsuji, S., et al. 2003. Aliment Pharmacol Ther. 18 Suppl 1: 82-9. PMID: 12925144
4. Discovery by Jaworski of Helicobacter pylori and its pathogenetic role in peptic ulcer, gastritis and gastric cancer.  |  Konturek, JW. 2003. J Physiol Pharmacol. 54 Suppl 3: 23-41. PMID: 15075463
5. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island.  |  Viala, J., et al. 2004. Nat Immunol. 5: 1166-74. PMID: 15489856
6. An endangered species in the stomach.  |  Blaser, MJ. 2005. Sci Am. 292: 38-45. PMID: 15715390
7. Helicobacter pylori duodenal colonization is a strong risk factor for the development of duodenal ulcer.  |  Pietroiusti, A., et al. 2005. Aliment Pharmacol Ther. 21: 909-15. PMID: 15801926
8. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.  |  Le, PN., et al. 2015. Pharmacol Ther. 146: 1-11. PMID: 25172549
9. The γ-OMP Algorithm for Feature Selection With Application to Gene Expression Data.  |  Tsagris, M., et al. 2022. IEEE/ACM Trans Comput Biol Bioinform. 19: 1214-1224. PMID: 33035156
10. Anti-NOTCH1 therapy with OMP-52 M51 inhibits salivary adenoid cystic carcinoma by depressing epithelial-mesenchymal transition (EMT) process and inducing ferroptosis.  |  Li, R., et al. 2024. Toxicol Appl Pharmacol. 484: 116825. PMID: 38253083
11. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.  |  Marshall, BJ. and Warren, JR. 1984. Lancet. 1: 1311-5. PMID: 6145023
12. Ultrastructural localization of urease of Helicobacter pylori.  |  Bode, G., et al. 1993. Med Microbiol Immunol. 182: 233-42. PMID: 8283959

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Helicobacter pylori OMP Antibody (BDI176) has 2 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Helicobacter pylori OMP Antibody (BDI176) Specifications

Alternate Product Name: Helicobacter pylori OMP

Product Clone Name: BDI176

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target:

Epitope Species: Helicobacter pylori

Product Reactivity/Detection: outer membrane protein (OMP) and heat shock protein (HSP) of Helicobacter pylori origin

Species Reactivity/Detection: NSR

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF

Vialing Information: Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for Helicobacter pylori OMP Antibody (BDI176): N/A